Michael Leonard Rich, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis, Multidrug-Resistant | 30 | 2024 | 912 | 2.430 |
Why?
|
| Antitubercular Agents | 26 | 2024 | 1320 | 1.800 |
Why?
|
| Nitroimidazoles | 5 | 2022 | 106 | 0.760 |
Why?
|
| Oxazoles | 5 | 2022 | 189 | 0.460 |
Why?
|
| Contraception Behavior | 1 | 2015 | 185 | 0.450 |
Why?
|
| Rwanda | 10 | 2015 | 703 | 0.440 |
Why?
|
| Family Planning Services | 1 | 2015 | 263 | 0.420 |
Why?
|
| Culture | 1 | 2015 | 632 | 0.380 |
Why?
|
| Tuberculosis, Pulmonary | 6 | 2015 | 811 | 0.380 |
Why?
|
| Directly Observed Therapy | 7 | 2014 | 137 | 0.350 |
Why?
|
| Social Support | 4 | 2014 | 2118 | 0.340 |
Why?
|
| HIV | 2 | 2012 | 1604 | 0.310 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 4 | 2015 | 92 | 0.300 |
Why?
|
| Clofazimine | 2 | 2023 | 33 | 0.280 |
Why?
|
| Residence Characteristics | 2 | 2015 | 2050 | 0.270 |
Why?
|
| Attitude to Health | 1 | 2015 | 2052 | 0.270 |
Why?
|
| Motivation | 1 | 2015 | 1971 | 0.260 |
Why?
|
| Sputum | 5 | 2021 | 476 | 0.250 |
Why?
|
| Rifampin | 4 | 2023 | 315 | 0.250 |
Why?
|
| Medication Adherence | 2 | 2014 | 2063 | 0.250 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 1872 | 0.240 |
Why?
|
| Anti-Retroviral Agents | 2 | 2012 | 1714 | 0.230 |
Why?
|
| HIV Infections | 7 | 2015 | 16715 | 0.210 |
Why?
|
| Mycobacterium tuberculosis | 8 | 2017 | 1832 | 0.180 |
Why?
|
| Anti-HIV Agents | 2 | 2014 | 4255 | 0.180 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 6 | 2017 | 564 | 0.170 |
Why?
|
| Fluoroquinolones | 2 | 2022 | 308 | 0.160 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2014 | 2560 | 0.160 |
Why?
|
| Plague | 1 | 2018 | 22 | 0.160 |
Why?
|
| Ofloxacin | 1 | 2017 | 65 | 0.150 |
Why?
|
| Rural Population | 6 | 2014 | 2207 | 0.150 |
Why?
|
| Russia | 7 | 2014 | 408 | 0.140 |
Why?
|
| Pyrazinamide | 1 | 2015 | 54 | 0.130 |
Why?
|
| Sex Education | 1 | 2015 | 93 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 1070 | 0.120 |
Why?
|
| Peru | 5 | 2011 | 882 | 0.120 |
Why?
|
| Isoniazid | 1 | 2015 | 274 | 0.110 |
Why?
|
| Treatment Outcome | 18 | 2024 | 63042 | 0.110 |
Why?
|
| Hospitals, District | 2 | 2013 | 106 | 0.110 |
Why?
|
| Community Health Services | 2 | 2015 | 650 | 0.110 |
Why?
|
| Drug Administration Schedule | 4 | 2015 | 4931 | 0.110 |
Why?
|
| Tuberculosis | 2 | 2020 | 1914 | 0.100 |
Why?
|
| Epidemics | 1 | 2018 | 523 | 0.100 |
Why?
|
| Electrolytes | 2 | 2022 | 282 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2015 | 2027 | 0.100 |
Why?
|
| Family Characteristics | 1 | 2016 | 1000 | 0.100 |
Why?
|
| Government Programs | 2 | 2018 | 275 | 0.090 |
Why?
|
| Developed Countries | 1 | 2013 | 437 | 0.090 |
Why?
|
| Bacteriological Techniques | 1 | 2011 | 277 | 0.090 |
Why?
|
| Research Design | 1 | 2006 | 5983 | 0.090 |
Why?
|
| Drug Therapy, Combination | 4 | 2015 | 6487 | 0.090 |
Why?
|
| Drug Design | 1 | 2015 | 1075 | 0.090 |
Why?
|
| Communicable Disease Control | 3 | 2011 | 856 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2012 | 420 | 0.090 |
Why?
|
| Gender Identity | 1 | 2015 | 686 | 0.090 |
Why?
|
| Clinical Protocols | 3 | 2024 | 1459 | 0.080 |
Why?
|
| Cohort Studies | 8 | 2022 | 40545 | 0.080 |
Why?
|
| Diffusion of Innovation | 1 | 2013 | 725 | 0.080 |
Why?
|
| Humans | 42 | 2024 | 743811 | 0.080 |
Why?
|
| Developing Countries | 2 | 2013 | 2815 | 0.080 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2017 | 1870 | 0.070 |
Why?
|
| Viral Load | 2 | 2014 | 3300 | 0.070 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 3850 | 0.070 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 251 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2012 | 970 | 0.070 |
Why?
|
| Qualitative Research | 1 | 2015 | 2682 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 1503 | 0.070 |
Why?
|
| Rural Health Services | 1 | 2009 | 380 | 0.070 |
Why?
|
| Young Adult | 5 | 2021 | 56392 | 0.070 |
Why?
|
| Adult | 16 | 2021 | 213889 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2014 | 5319 | 0.070 |
Why?
|
| Female | 20 | 2024 | 380020 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2011 | 953 | 0.060 |
Why?
|
| Information Dissemination | 1 | 2013 | 1099 | 0.060 |
Why?
|
| Retrospective Studies | 14 | 2016 | 77410 | 0.060 |
Why?
|
| Retreatment | 1 | 2006 | 609 | 0.060 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2011 | 1320 | 0.060 |
Why?
|
| Male | 19 | 2021 | 349776 | 0.060 |
Why?
|
| RNA, Viral | 1 | 2012 | 2901 | 0.060 |
Why?
|
| Prisoners | 1 | 2006 | 297 | 0.050 |
Why?
|
| Prospective Studies | 5 | 2022 | 53250 | 0.050 |
Why?
|
| Algorithms | 1 | 2023 | 13869 | 0.050 |
Why?
|
| Child | 6 | 2021 | 77637 | 0.050 |
Why?
|
| World Health Organization | 2 | 2022 | 1317 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 57744 | 0.050 |
Why?
|
| Aged | 8 | 2021 | 163178 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2012 | 2683 | 0.050 |
Why?
|
| Program Development | 1 | 2007 | 1314 | 0.050 |
Why?
|
| Program Evaluation | 2 | 2006 | 2483 | 0.050 |
Why?
|
| Middle Aged | 9 | 2021 | 213241 | 0.050 |
Why?
|
| Child Mortality | 2 | 2014 | 198 | 0.050 |
Why?
|
| Pregnancy | 3 | 2024 | 29140 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 3921 | 0.050 |
Why?
|
| Live Birth | 1 | 2024 | 512 | 0.050 |
Why?
|
| Latvia | 2 | 2011 | 14 | 0.040 |
Why?
|
| Health Services Accessibility | 2 | 2015 | 5136 | 0.040 |
Why?
|
| Estonia | 2 | 2011 | 53 | 0.040 |
Why?
|
| Philippines | 2 | 2011 | 86 | 0.040 |
Why?
|
| Logistic Models | 2 | 2012 | 13404 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2020 | 230 | 0.040 |
Why?
|
| Yersinia pestis | 1 | 2018 | 33 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2005 | 1546 | 0.040 |
Why?
|
| Madagascar | 1 | 2018 | 117 | 0.040 |
Why?
|
| Depression | 2 | 2014 | 7760 | 0.030 |
Why?
|
| Poverty | 1 | 2007 | 2660 | 0.030 |
Why?
|
| Adolescent | 6 | 2021 | 85729 | 0.030 |
Why?
|
| Pilot Projects | 3 | 2016 | 8316 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2009 | 4370 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2021 | 2307 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 601 | 0.030 |
Why?
|
| Internationality | 1 | 2018 | 1002 | 0.030 |
Why?
|
| Prevalence | 3 | 2017 | 15211 | 0.030 |
Why?
|
| Public Health | 2 | 2018 | 2603 | 0.030 |
Why?
|
| Decision Trees | 1 | 2013 | 506 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2014 | 496 | 0.020 |
Why?
|
| Quality of Life | 1 | 2012 | 12788 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2013 | 724 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2014 | 10251 | 0.020 |
Why?
|
| Registries | 1 | 2005 | 8090 | 0.020 |
Why?
|
| Heart Failure | 1 | 2013 | 10896 | 0.020 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 7784 | 0.020 |
Why?
|
| Ambulatory Care | 2 | 2011 | 2707 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 935 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2024 | 25609 | 0.020 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2009 | 214 | 0.020 |
Why?
|
| Incidence | 1 | 2006 | 20948 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2008 | 211 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2007 | 299 | 0.020 |
Why?
|
| Microscopy | 1 | 2011 | 896 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2013 | 941 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2012 | 2538 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 9944 | 0.020 |
Why?
|
| Risk Factors | 2 | 2016 | 72252 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 1404 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2007 | 469 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2013 | 6356 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2014 | 6457 | 0.010 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2004 | 103 | 0.010 |
Why?
|
| Health Resources | 1 | 2009 | 912 | 0.010 |
Why?
|
| Psychometrics | 1 | 2012 | 3000 | 0.010 |
Why?
|
| Health Surveys | 1 | 2012 | 4036 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2012 | 6030 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2003 | 376 | 0.010 |
Why?
|
| Health Policy | 1 | 2014 | 2662 | 0.010 |
Why?
|
| Self Report | 1 | 2012 | 3550 | 0.010 |
Why?
|
| Echocardiography | 1 | 2013 | 5096 | 0.010 |
Why?
|
| Time Factors | 2 | 2013 | 40038 | 0.010 |
Why?
|
| National Health Programs | 1 | 2004 | 445 | 0.010 |
Why?
|
| Leadership | 1 | 2009 | 1357 | 0.010 |
Why?
|
| Data Collection | 1 | 2009 | 3339 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 39001 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2005 | 2617 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 2007 | 1771 | 0.010 |
Why?
|
| Sex Factors | 1 | 2012 | 10394 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2007 | 1438 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8637 | 0.010 |
Why?
|
| International Cooperation | 1 | 2003 | 1419 | 0.010 |
Why?
|
| Health Personnel | 1 | 2009 | 3217 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 15067 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2011 | 40964 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15526 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2009 | 4687 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 19894 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2007 | 3155 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 3608 | 0.010 |
Why?
|
| Infant | 1 | 2011 | 35122 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 7270 | 0.000 |
Why?
|